Christopher G. Kanakry, M.D.
Lasker Clinical Research Scholar
Experimental Transplantation and Immunotherapy Branch
10-CRC, Room 4-3142
Bethesda, MD 20892
Dr. Kanakry’s research is in transplantation immunology and graft-versus-host disease, particularly focused on better understanding the immunologic mechanisms by which post-transplantation cyclophosphamide prevents graft-versus-host disease in order to rationally improve transplantation platforms using this approach. His work has disproven the previously widely accepted paradigm that post-transplantation cyclophosphamide works by selectively eliminating alloreactive T cells. He has shown in humans and mice that regulatory T cells preferentially recover after post-transplantation cyclophosphamide and are necessary in murine models for post-transplantation cyclophosphamide’s activity in preventing graft-versus-host disease. More recently, he has shown that post-transplantation cyclophosphamide does not eliminate alloreactive T cells, but instead induces their functional impairment. He also has published multiple clinical studies on the use of post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis in human leukocyte antigen-matched and -haploidentical allogeneic hematopoietic cell transplantation. His current work centers on developing a comprehensive new model for understanding graft-versus-host disease prevention by post-transplantation cyclophosphamide in mice and translating these new findings to the clinic in early phase clinical studies.
Dr. Kanakry received his undergraduate degree from Harvard College and his MD from Duke University School of Medicine. He completed his Internal Medicine residency and Hematology/Medical Oncology fellowships at the Johns Hopkins University School of Medicine, where he also carried out transplantation research under the mentorship of Dr. Leo Luznik. Dr. Kanakry joined the NCI at the end of 2014 as an Assistant Clinical Investigator and was awarded a Lasker Clinical Research Scholar tenure-track position within NCI in October, 2018.
Kanakry CG, Coffey DG, Towlerton AM, Vulic A, Storer BE, Chou J, Yeung CC, Gocke CD, Robins HS, O'Donnell PV, Luznik L, Warren EH. Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight. 2016;1(5).
Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10-24.
Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124(25):3817-27.
Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32(31):3497-505.
Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, Fuchs EJ, Jones RJ, Hess AD, Luznik L. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.
Related Scientific Focus Areas
This page was last updated on October 25th, 2019